Codexis Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
Codexis, Inc.
Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --...
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
August 02, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular...
Codexis Announces CEO Transition Effective August 9, 2022
July 18, 2022 16:05 ET
|
Codexis, Inc.
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY,...
Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
July 14, 2022 16:06 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company...
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
July 14, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced preliminary...
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
June 17, 2022 08:00 ET
|
Codexis, Inc.
Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the...
Codexis to Participate in Upcoming Healthcare Conferences
May 25, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that...
Codexis to Participate in Upcoming Healthcare Conferences
May 17, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that management...
Codexis Presents Pre-Clinical Data Highlighting Gene Therapy Programs at the ASGCT 25th Annual Meeting
May 16, 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that three of its...
Codexis Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET
|
Codexis, Inc.
Total Revenue up 96% and Product Revenue up 200% YOY; Product Gross Margin Expands to 72% Reiterating Guidance for 2022, Including Total Revenue of $152 - $158M REDWOOD CITY Calif., May 05, 2022 ...